State Medicaid Programs Face Operational Changes as 340B Shifts from Discount to Rebate Model in 2026

HRSA is launching a pilot program in January 2026 that fundamentally changes how the 340B drug pricing program works—moving from upfront discounts to a rebate model for 10 high-cost drugs subject to Medicare price negotiation. This shift has direct implications for state Medicaid programs and their managed care plans, particularly around duplicate discount prevention, claims processing, pharmacy reimbursement, and financial reconciliation processes that have been built around the traditional 340B discount structure for over 30 years. States need to assess operational readiness now to handle the accounting and reporting changes this model introduces.

Pharmacy · Managed Care · Finance

This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.

More from Milliman